Drug delivery to the posterior segment of the eye

European Journal of Ophthalmology

Volumn 21, Issue SUPPL.6, 2011, Pages 20-26

  Fischer, Naomi ^a   Narayanan, Raja ^b   Loewenstein, Anat ^a   Kuppermann, Baruch D ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b L V PRASAD EYE INSTITUTE   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood ocular barrier; Drug delivery; Extended release; Intravitreal; Posterior segment

Indexed keywords

ANECORTAVE; ATG 3; BEVACIZUMAB; BRIMONIDINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; DRUG CARRIER; FLUOCINOLONE ACETONIDE; GANCICLOVIR; ILUVIEN; METHYLPREDNISOLONE SODIUM SUCCINATE; OC 10X; OT 551; PAZOPANIB; PLACEBO; PRODRUG; RANIBIZUMAB; TARGEGEN 801; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ARTICLE; BLOOD EYE BARRIER; CYTOMEGALOVIRUS RETINITIS; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RELEASE; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; IONTOPHORESIS; JUXTASCLERAL DRUG ADMINISTRATION; LOW DRUG DOSE; OPEN ANGLE GLAUCOMA; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; UVEITIS;

BLOOD-RETINAL BARRIER; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; INFUSION PUMPS, IMPLANTABLE; INTRAVITREAL INJECTIONS; NANOPARTICLES; OPHTHALMIC SOLUTIONS; POSTERIOR EYE SEGMENT;

EID: 79960982776     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.6051     Document Type: Article

References (26)

1. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57: 2010-32.
2. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-5.
3. Chiou GC, Watanabe K. Drug delivery to the eye. Pharmacol Ther 1982; 17: 269-78.
4. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985; 26: 584-7.
5. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000; 41: 961-4.
6. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002; 47(suppl 1): S41-52.
7. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995; 36: 1893-903.
8. Ni Z, Hui P. Emerging pharmacologic therapies for wet agese related macular degeneration. Ophthalmologica 2009; 223: 401-10.
9. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-21.
10. Wirtz R. Die Ionentherapie in der Augenheilkunde. Klin Monatsbl Augenheilkd 1908; 46: 543-9.
11. Guy J. New therapies for optic neuropathies: development in experimental models. Curr Opin Ophthalmol 2000; 11: 421-9.
12. Halhal M, Renard G, Bejjani RA, Behar-Cohen F. [Corneal graft rejection and corticoid iontophoresis: 3 case reports.] J Fr Ophtalmol 2003; 26: 391-5.
13. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005; 139: 290-4.
14. Venkatesh P, Abhas Z, Garg S, Vohra R. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 2006; 245: 59-67.
15. Byun YS, Park YH. Complications and safety profile of pos-terior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009; 25: 159-62.
16. Russell SR, Hudson HL, Jerdan JA, Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration: a review of clinical outcomes. Surv Ophthalmol 2007; 52(suppl 1): S79-90.
17. Rosenfeld PJ, Brown DM, Heier JS, et al, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
18. Brown DM, Kaiser PK, Michels M, et al, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
19. Bhavsar AR, Googe JM Jr, Stockdale CR, et al, Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009; 127: 1581-3.
20. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993; 168: 1506-9.
21. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994; 112: 1531-9.
22. Pearson P, Levy B, Comstock T, Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Invest Ophthalmol Vis Sci 2006; 47: E-Abstract 5442.
23. Form 8-K filed to the United States Securities and Exchange Commission by PsiVida Corporation on December 23, 2009, which reported the 24-month results of the two phase 3 pivotal clinical trials (FAME™ Study) for Iluvien® in the treatment of diabetic macular edema.
24. Kuppermann BD, Blumenkranz MS, Haller JA, et al, Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-17.
25. Haller JA, Bandello F, Belfort R Jr, et al, OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-46.
26. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010; 224 (Suppl 1): 46-53.